Luye Pharma Group Ltd. (FRA:LUP)

Market Cap	723.23M -49.1%
Revenue (ttm)	789.81M -0.6%
Net Income	89.73M +75.4%
EPS	0.02 +64.5%
Shares Out	n/a
PE Ratio	7.82
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,359
Open	0.1780
Previous Close	0.1800
Day's Range	0.1780 - 0.1780
52-Week Range	0.1780 - 0.3540
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 11, 2026

About Luye Pharma Group

Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally. The company offers Lipusu, for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema and edema caused by traum...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 5,270
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: LUP

Financial Performance

In 2025, Luye Pharma Group's revenue was 6.31 billion, an increase of 4.07% compared to the previous year's 6.06 billion. Earnings were 618.75 million, an increase of 31.12%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error